| Name | Title | Contact Details |
|---|
Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.
Sustainable Bioproducts has developed a breakthrough protein production platform for a variety of consumer and industrial applications.
Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.
Leading with purpose; Briotech is dedicated to change health, healing, and disinfection with our proven pure HOCl and create jobs & partnerships globally.